View Alert
Originator: MHRA Drug Alerts

From: Alison Bunce - Medicines and Healthcare Products Regulatory Agency

Issue date: 05-Oct-2018 12:00:09

Action by recipients:
  • NHS Trusts (England) - Medical Director
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Regional Offices

Information to recipients:
  • Director of Public Health
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Chief Executive
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Clinical Commissioning Groups

Action category: Class 2: Action within 48 hours

Title: DRUG ALERT CLASS 2, ACTION WITHIN 48 HOURS, ALLERGAN PHARMACEUTICALS IRELAND, OZURDEX 700 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR.

Broadcast content: Recall of a number of batches due to the possibility of contamination with a single loose particle of silicone which may become detached from the needle sleeve during administration of the implant and may be delivered into the eye along with the implant. 

Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts 

We understand that this product is used in the hospital setting and is unlikely to be used in General Practice or Community Pharmacy. Please do not send  this communication to Community Pharmacists or to GPs. 



Alert reference: EL (18)A/16

Attachments:
Cascade to:
  • #HospitalPharmacy#


Contact our helpdesk

Telephone: 020 3080 6747
Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency